Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 4 2Phase 1 2Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 4Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 3499Neoplasms 2740Prostatic Neoplasms 1583Colorectal Neoplasms 1248Lung Neoplasms 1188Motor Activity 766Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 560Carcinoma, Hepatocellular 559Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 438Anxiety Disorders 401Ovarian Neoplasms 399Pain 376Esophageal Neoplasms 347Polycystic Ovary Syndrome 341Neoplasm Metastasis 340Fatigue 324Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 286Multiple Myeloma 283Endometrial Neoplasms 263Lymphoma 258Hematologic Neoplasms 251

Interventions

pazopanib 2Sorafenib 2Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase NA × OTHER × Refractory Solid Tumors × Clear all
NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Withdrawn
Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡